Interventions
obesity, transfusion-related reactions
ADVERSE EVENTS, OBESITY, COMPLICATIONS
Of the 136 randomized enrolled participants, 68 received a single dose of CPT and 5-day of FPV treatment, while 68 received a sotrovimab single dose. In the CPT arm, ABO-compatible CCP was transfused to patients, with a volume of 250 mL for <60 kg recipients and 300 mL for >60 kg recipients. The infusion was completed within 2 hours, with close monitoring for transfusion-related reactions and adverse events, promptly treating any observed complications. The patients received 3,600 mg of FPV loading dose on day 0 and 1,600 mg per day of FPV from days 1–4. In a patient with obesity, the FPV loading dose was 4,800 mg on day 0, then 2,000 mg per day of FPV on days later. In the sotrovimab arm, the participants received a single dose of 500 mg of intravenous sotrovimab within 1 hour. The participants received clinical, laboratory, virologic, and radiologic evaluations on days 2, 5, 14, and 28–42 and were evaluated at the outpatient clinic.